EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which along
with other PRC2 components mediates gene expression suppression via the methylation of …

The polycomb repressive complex 2 (PRC2) consists of three core components EZH2,
SUZ12 and EED. EZH2 catalyzes the methylation of lysine 27 of histone H3, a modification …

Enhancer of zeste homolog (EZH2) is a key epigenetic regulator of gene expression and is
frequently overexpressed in various cancer types, suggesting a role in oncogenesis. The …

The number of patients with diabetic nephropathy (DN) is still on the rise worldwide, and this
requires the development of new therapeutic strategies. Recent reports have highlighted …

Recent progress in cancer immunotherapy highlights the power of the immune system to
control tumors, although a small patient subset responds to current immunotherapies …

Immune checkpoint blockade (ICB) has demonstrated clinical success in “inflamed” tumors
with substantial T cell infiltrates, but tumors with an immune-desert tumor microenvironment …

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The
accumulation of genetic and epigenetic changes is closely related to the occurrence and …

Enhancer of zeste 2 (EZH2) is the catalytic subunit of the Polycomb Repressive Complex 2
(PRC2) that mediates di-and trimethylation of histone 3 lysine 27 effectively precluding …

T cell senescence and exhaustion are major barriers to successful cancer immunotherapy.
Here we show that miR-155 increases CD8+ T cell antitumor function by restraining T cell …

Cytotoxic T cell differentiation is guided by epigenome adaptations, but how epigenetic
mechanisms control lymphocyte development has not been well defined. Here we show that …